Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy of claseprubart DNTH103 compared to placebo in adults with chronic inflammatory demyelinating polyneuropathy CIDP. This Phase 3 study aims to assess whether claseprubart can improve outcomes in participants with typical or variant forms of CIDP, including motor or multifocal types. The study is sponsored by Dianthus Therapeutics and involves several treatment periods to carefully measure the drugs impact. The study consists of multiple parts Part A includes an open-label phase lasting up to 13 weeks where participants receive an intravenous loading dose of claseprubart followed by subcutaneous injections every two weeks. Part B is a randomized, double-blind period lasting up to 52 weeks where participants who responded in Part A receive either claseprubart or placebo as subcutaneous injections every two weeks. Eligible participants may then join an optional open-label extension lasting up to 104 weeks receiving claseprubart injections every two weeks. A safety follow-up period of 40 weeks follows to monitor long-term effects. Participants will undergo various assessments throughout the study, including evaluations of neurological function and disease activity using scales such as the Adjusted Inflammatory Neuropathy Cause and Treatment INCAT score, Inflammatory Rasch-built Overall Disability Scale I-RODS, grip strength measurements, and other strength and disability scales. Researchers will also monitor for adverse events, measure serum drug concentrations, and evaluate immune responses. The total participation time may extend over several years, with regular visits for treatment administration, monitoring, and safety follow-up.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the nutritional status, body composition, dietary intakes, and related biochemical and clinical parameters of Filipino pediatric patients diagnosed with Inborn Errors of Intermediary Protein Metabolism IEIPM. This includes amino acid disorders, organic acidemias, and urea cycle defects. The study aims to better understand the nutritional challenges faced by children from newborn to 18 years old with IEIPM, as well as the caregivers experiences managing these conditions under special dietary needs. This research supports the development of tailored nutrition policies and programs in the Philippines for this rare disease population. Participants include pediatric patients diagnosed with IEIPM who are receiving medical and dietary treatment, along with age- and sex-matched healthy children as controls. The study compares nutritional status, body composition, dietary intake, and clinical indicators at baseline, 6 months, and 12 months. Data on natural and medical food consumption, protein-energy ratios, and biochemical markers will be collected to assess adequacy and associations with growth and health outcomes. During the 12-month study, participants will undergo evaluations of weight, heightlength, head circumference, fat and lean mass, bone mineral density, and dietary intake at specified intervals. Blood samples will be analyzed for amino acid levels, vitamins, minerals, and anemia risk. Caregivers will also provide information about dietary management experiences. This comprehensive assessment aims to guide improved nutritional care and support for pediatric IEIPM patients in the local healthcare setting.